Immune cell-antibody interactions in health and disease

Sophia N Karagiannis; James N Arnold

doi:10.1093/cei/uxac065

Immune cell-antibody interactions in health and disease

Sophia N Karagiannis, James N Arnold

Research output: Contribution to journal › Article

5 Citations (Scopus)

43 Downloads (Pure)

Abstract

The human immune system safeguards against pathogens through a multitude of cellular and molecular signals, involving different components of the innate and adaptive response. Contrastingly, autoimmune diseases, allergic conditions and cancer evoke different aspects of these otherwise protective processes. Understanding the immunological hallmarks for each pathological setting is essential for improving prevention, diagnosis, prognosis and treatment. The activatory states of immune effector cells, especially in relation to their direct or indirect interactions with antibodies, are important determinants of an efficient, protective response that results in target clearance and improved clinical outcomes. Dysregulation of effector cells and their functions alongside alternatively activated humoral immune responses may contribute to several chronic diseases including allergic inflammation, autoimmune disorders and cancer. This Review Series brings to the forefront several key activation and regulatory features of immune effector cells in different diseases including cancer, infection allergy and autoimmunity. Specific attention is drawn on how antibodies can impact effector cell states, and their pro-inflammatory and immune protective functions. Articles in this Series discuss different effector cells and antibody isotypes in infection, inflammation, tolerance and cancer immune surveillance, covering basic and translational mechanisms, clinical and epidemiological insights into these immune responses. Understanding the critical attributes of immune cells, especially those needed to effectively engage antibodies, will undoubtedly help better exploit their potential for disease management and therapy.

Original language	English
Pages (from-to)	1-3
Number of pages	3
Journal	Clinical and Experimental Immunology
Volume	209
Issue number	1
Early online date	26 Jun 2022
DOIs	https://doi.org/10.1093/cei/uxac065
Publication status	Published - 22 Jul 2022

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1093/cei/uxac065

Karagiannis Arnold CEI uxac065

Cite this

@article{480fa15a00874169bad02689e594e50c,

title = "Immune cell-antibody interactions in health and disease",

abstract = "The human immune system safeguards against pathogens through a multitude of cellular and molecular signals, involving different components of the innate and adaptive response. Contrastingly, autoimmune diseases, allergic conditions and cancer evoke different aspects of these otherwise protective processes. Understanding the immunological hallmarks for each pathological setting is essential for improving prevention, diagnosis, prognosis and treatment. The activatory states of immune effector cells, especially in relation to their direct or indirect interactions with antibodies, are important determinants of an efficient, protective response that results in target clearance and improved clinical outcomes. Dysregulation of effector cells and their functions alongside alternatively activated humoral immune responses may contribute to several chronic diseases including allergic inflammation, autoimmune disorders and cancer. This Review Series brings to the forefront several key activation and regulatory features of immune effector cells in different diseases including cancer, infection allergy and autoimmunity. Specific attention is drawn on how antibodies can impact effector cell states, and their pro-inflammatory and immune protective functions. Articles in this Series discuss different effector cells and antibody isotypes in infection, inflammation, tolerance and cancer immune surveillance, covering basic and translational mechanisms, clinical and epidemiological insights into these immune responses. Understanding the critical attributes of immune cells, especially those needed to effectively engage antibodies, will undoubtedly help better exploit their potential for disease management and therapy.",

author = "Karagiannis, {Sophia N} and Arnold, {James N}",

note = "{\textcopyright} The Author(s) 2022. Published by Oxford University Press on behalf of the British Society for Immunology. Publisher Copyright: {\textcopyright} The Author(s) 2022. Published by Oxford University Press on behalf of the British Society for Immunology.",

year = "2022",

month = jul,

day = "22",

doi = "10.1093/cei/uxac065",

language = "English",

volume = "209",

pages = "1--3",

journal = "Clinical and Experimental Immunology",

issn = "0009-9104",

publisher = "Wiley-Blackwell Publishing Ltd",

number = "1",

}

TY - JOUR

T1 - Immune cell-antibody interactions in health and disease

AU - Karagiannis, Sophia N

AU - Arnold, James N

N1 - © The Author(s) 2022. Published by Oxford University Press on behalf of the British Society for Immunology. Publisher Copyright: © The Author(s) 2022. Published by Oxford University Press on behalf of the British Society for Immunology.

PY - 2022/7/22

Y1 - 2022/7/22

N2 - The human immune system safeguards against pathogens through a multitude of cellular and molecular signals, involving different components of the innate and adaptive response. Contrastingly, autoimmune diseases, allergic conditions and cancer evoke different aspects of these otherwise protective processes. Understanding the immunological hallmarks for each pathological setting is essential for improving prevention, diagnosis, prognosis and treatment. The activatory states of immune effector cells, especially in relation to their direct or indirect interactions with antibodies, are important determinants of an efficient, protective response that results in target clearance and improved clinical outcomes. Dysregulation of effector cells and their functions alongside alternatively activated humoral immune responses may contribute to several chronic diseases including allergic inflammation, autoimmune disorders and cancer. This Review Series brings to the forefront several key activation and regulatory features of immune effector cells in different diseases including cancer, infection allergy and autoimmunity. Specific attention is drawn on how antibodies can impact effector cell states, and their pro-inflammatory and immune protective functions. Articles in this Series discuss different effector cells and antibody isotypes in infection, inflammation, tolerance and cancer immune surveillance, covering basic and translational mechanisms, clinical and epidemiological insights into these immune responses. Understanding the critical attributes of immune cells, especially those needed to effectively engage antibodies, will undoubtedly help better exploit their potential for disease management and therapy.

AB - The human immune system safeguards against pathogens through a multitude of cellular and molecular signals, involving different components of the innate and adaptive response. Contrastingly, autoimmune diseases, allergic conditions and cancer evoke different aspects of these otherwise protective processes. Understanding the immunological hallmarks for each pathological setting is essential for improving prevention, diagnosis, prognosis and treatment. The activatory states of immune effector cells, especially in relation to their direct or indirect interactions with antibodies, are important determinants of an efficient, protective response that results in target clearance and improved clinical outcomes. Dysregulation of effector cells and their functions alongside alternatively activated humoral immune responses may contribute to several chronic diseases including allergic inflammation, autoimmune disorders and cancer. This Review Series brings to the forefront several key activation and regulatory features of immune effector cells in different diseases including cancer, infection allergy and autoimmunity. Specific attention is drawn on how antibodies can impact effector cell states, and their pro-inflammatory and immune protective functions. Articles in this Series discuss different effector cells and antibody isotypes in infection, inflammation, tolerance and cancer immune surveillance, covering basic and translational mechanisms, clinical and epidemiological insights into these immune responses. Understanding the critical attributes of immune cells, especially those needed to effectively engage antibodies, will undoubtedly help better exploit their potential for disease management and therapy.

UR - http://www.scopus.com/inward/record.url?scp=85135202662&partnerID=8YFLogxK

U2 - 10.1093/cei/uxac065

DO - 10.1093/cei/uxac065

M3 - Article

C2 - 35752999

SN - 0009-9104

VL - 209

SP - 1

EP - 3

JO - Clinical and Experimental Immunology

JF - Clinical and Experimental Immunology

IS - 1

ER -

Immune cell-antibody interactions in health and disease

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this